news
TAmiRNA at MEDICA Düsseldorf
TAmiRNA Senior Scientist Teresa Lara Krammer will attend MEDICA Düsseldorf next week to speak about “thrombomiRs - circulating microRNAs as novel platelet activation markers?”. Reach out to Teresa directly to meet with her before or after her presentation on Tuesday, Nov. 14th at 14:50, Halle1/G37 and discuss our latest developments and how TAmiRNA’s products and services can assist your business! [...]
TAmiRNA at Extracellular Vesicles Forum
TAmiRNA Scientific Consultant Magdalena Mecking is attending the Extracellular Vesicles Forum on Oct 10th – 11th in Cambridge. Stop by one of her posters and learn more about how TAmiRNA’s service may benefit your EV project! Reach out to Magdalena directly and discuss our latest developments and how TAmiRNA's services can assist your business!
Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney
We want to draw your attention to our latest publication which appeared in American Journal of Physiology-Renal Physiology. We could show that laser microdissection combined with (small) RNA sequencing revealed renal microvascular compartment-specific miRNA and mRNA expression profiles. Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney Luxen M, Zwiers PJ, Meester F et al. Am J Physiol Renal Physiol. 2023 [...]
TAmiRNA at RNA Leaders conference
TAmiRNA CEO/CSO Matthias Hackl will attend the RNA Leaders conference in Boston next week to speak about how cell-free RNA biomarkers can be incorporated in pre-clinical and clinical development to inform about drug safety, drug targeting, and drug efficacy. Reach out to Matthias directly to meet with him before or after his presentation on Thursday, Sept. 7th at 4:30 pm ET and discuss our [...]
TAmiRNA presenting miND® NextGen sequencing opportunities at ISSX/DMDG 2023 Meeting
TAmiRNA will be a significant contributor to the inaugural joint European meeting of the ISSX and DMDG respectively focused on xenobiotics and drug metabolics. Dr. Matthias Hackl, CEO and co-founder, will take part in the discussions of Symposium 4: ‘MicroRNAs as Biomarkers of Clinical Drug-induced Organ Injury’ (Tuesday, June 13, 1000-1200 hrs). Dr. Hackl’s presentation ‘miRNA Biomarker Development: Pitfalls and Best Practices for [...]
TAmiRNA at RNA Society Annual Meeting, 30 May – 4 June 2023, Singapore
TAmiRNA Senior Scientist Dr. Kseniya Khamina-Kotisch will present Poster 46 ‘Identification of novel circulating MicroRNA Biomarkers of Central Nervous System Damage by absolute quantitation using a MicroRNA Next-Generation Sequencing Discovery (miND) Assay’. She will also present Poster 66: ‘Comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs) in cells, plasma, urine, and extracellular vesicles’. Take advantage, meet Kseniya [...]
We are proud to announce our ISO 13485:2016 certification
Today we announce that TAmiRNA has received ISO 13485:2016 certification for its Medical Device and Quality Management System after successfully completing the audit through Germany-based notified body MDC. This ISO certification indicates that TAmiRNAs quality management system meets the most current regulatory requirements applicable to the medical device industry. "We are very proud of this certification as it demonstrates the commitment of our [...]
Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjectsPlasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects
biomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring
Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects
We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising biomarker candidates for monitoring the extent of platelet inhibition. This could enable stratification of patients depending on their response to antiplatelet therapy and guide treatment decisions. click here to read [...]
Biogenity Joins Forces with TAmiRNA
The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release
miND spike-in
TAmiRNA has launched an innovative NGS technology for absolute quantitation of miRNAs and other small RNAs , the miND® (microRNA Next-Generation Sequencing Discovery) spike-in. The miND® spike-in has been developed for small RNA sequencing experiments and absolute quantitation of microRNAs in any biological matrix and species, overcoming previous challenges of quality control and difficulty in achieving absolute quantitation of miRNAs across different biological [...]